GlaxoSmithKline: Poliomyelitis trials

The registry lists 44 Poliomyelitis studies with GlaxoSmithKline as lead sponsor. 0 are open to participants now and 30 have results posted.

Phase 1 1Phase 2 10Phase 3 20Phase 4 10No phase 3(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Evaluation of Immunogenicity and Safety of a Booster Dose of Infanrix Hexa™ in Healthy Infants Born to Mothers Vaccinated With Boostrix™ During Pregnancy or Immediately Post-deliveryCompletedNCT02853929Phase 4Results posted
• Immunogenicity and Safety Study of Infanrix Hexa in Healthy Infants Born to Mothers Vaccinated With Boostrix™ During Pregnancy or Immediately Post-deliveryCompletedNCT02422264Phase 4Results posted
• Study to Determine the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals; Infanrix Hexa at 2, 4 and 6 Months of Age in Healthy InfantsCompletedNCT02096263Phase 3Results posted
• Safety of GSK Biologicals' Infanrix-IPV+HibTM Vaccine in Healthy Vietnamese ToddlersCompletedNCT01577732Phase 3Results posted
• Safety and Immunogenicity of a Booster Dose of New Formulations of GlaxoSmithKline Biologicals' DTPa-HBV-IPV/Hib Vaccine (GSK217744)CompletedNCT01453998Phase 2Results posted
• Study to Evaluate Antibody Persistence in Children Previously Vaccinated With Infanrix Hexa™ or Infanrix-IPV/Hib™CompletedNCT01358825Phase 4Results posted
• Immunogenicity and Safety Study in Infants of GlaxoSmithKline Biologicals' Infanrix Hexa™ (DTPa-HBV-IPV/Hib) VaccineCompletedNCT01353703Phase 3Results posted
• Immunogenicity and Safety of Booster Dose of BoostrixTM Polio Vaccine in Previously Boosted AdultsCompletedNCT01323959Phase 4Results posted
• Immunogenicity and Safety of Booster Dose of PoliorixTM Vaccine in Previously Vaccinated ToddlersCompletedNCT01323647Phase 3Results posted
• Immunogenicity and Safety of GlaxoSmithKline Biologicals' Infanrix™-IPV+Hib VaccineCompletedNCT01309646Phase 3Results posted
• Safety and Immunogenicity of New Formulations of GlaxoSmithKline Biologicals' DTPa-HBV-IPV/Hib Vaccine (GSK217744)CompletedNCT01248884Phase 2Results posted
• Immunogenicity and Safety of GSK Biologicals' Boostrix Polio Vaccine in 3 and 4-year-old ChildrenCompletedNCT01245049Phase 3Results posted
• Immunogenicity and Safety Study of GlaxoSmithKline Biologicals' GSK2202083A Vaccine Administered as a Booster DoseCompletedNCT01171989Phase 2Results posted
• Study to Evaluate the Safety of Co-administration of GSK Biologicals' Poliorix and Infanrix in Healthy Children in RussiaCompletedNCT01094171Phase 4Results posted
• Study of GlaxoSmithKline Biologicals' GSK2202083A Vaccine in Healthy InfantsCompletedNCT01090453Phase 2Results posted
• Immunogenicity and Safety Study of GSK Biologicals' Infanrix-IPV+Hib™ VaccineCompletedNCT01086423Phase 3Results posted
• Immunogenicity and Safety Study of GlaxoSmithKline Biologicals' Poliorix™ VaccineCompletedNCT01021293Phase 3Results posted
• Immunogenicity and Safety Study of GSK Biologicals' GSK2202083A Vaccine in Healthy Infants at 2, 3 and 4 Months of AgeCompletedNCT00970307Phase 2Results posted
• Safety Study of GSK Biologicals' DTPa-IPV/Hib (Infanrix™-IPV/Hib)CompletedNCT00964028Phase 3Results posted
• Safety and Reactogenicity of GSK Biologicals' Inactivated Poliomyelitis Vaccine (IPV) (Poliorix) in InfantsCompletedNCT00937404Phase 1Results posted
• Safety and Reactogenicity of GlaxoSmithKline (GSK) Biologicals' IPV Vaccine (PoliorixTM) in ToddlersCompletedNCT00920439Phase 3Results posted
• Feasibility Study of GlaxoSmithKline Biologicals' GSK2202083A Vaccine in Healthy Infants at 3, 5 and 11 Months of Age.TerminatedNCT00871741Phase 2Results posted
• Immunogenicity and Safety of Boostrix Polio Vaccine as a Booster Dose in 5 to 6-year-old Children.CompletedNCT00871000Phase 3Results posted
• Immunogenicity and Safety of GSK Biologicals' Infanrix Hexa in InfantsCompletedNCT00753649Phase 4Results posted
• Safety and Immunogenicity of a Booster Dose of GSK Biological's Boostrix-Polio VaccineCompletedNCT00635128Phase 4Results posted
• Immunogenicity and Reactogenicity of a Booster Dose of GSK Bio's DTPa-HBV-IPV/Hib VaccineCompletedNCT00627458Phase 2Results posted
• Study of a New Formulation of DTPa-HBV-IPV/Hib Vaccine Administered as a Booster Dose to 18-23 Months Old ChildrenCompletedNCT00611559Phase 4Results posted
• Pneumococcal Vaccine Booster Study in Healthy Children 11-18 Months Old Previously Primed With the Same VaccinesCompletedNCT00463437Phase 3Results posted
• Assess the Safety & Reactogenicity of DTPa-IPV/Hib Vaccine Administered at 3, 4, 5 & 18 Mths of Age, in Healthy InfantsCompletedNCT00325156Phase 4Results posted
• Safety of DTPa-IPV/Hib & DTPa-HBV-IPV/Hib, Followed by DTPa-IPV/Hib Vaccine in Infants Who Received Hepatitis B VaccineCompletedNCT00325143Phase 3Results posted
• Evaluation of Immunogenicity and Safety of DTPa-IPV/Hib Conjugate Vaccine (Infanrix™-IPV/Hib) Administered at 6, 10 and 14 Weeks in Healthy Indian InfantsWithdrawnNCT03128489Phase 3
• Post-marketing Surveillance to Assess the Safety of Infanrix-IPV Vaccine Among Infants and Children in KoreaCompletedNCT01568060
• Immunogenicity and Reactogenicity of DTPa-HBV-IPV/Hib Vaccine Followed by the Same Vaccine and Oral Polio VaccineCompletedNCT01457560Phase 3
• Comparison of Immunogenicity and Reactogenicity of INFANRIX™ HEXA and HEXAVAC™ Vaccines as a Primary Vaccination CourseCompletedNCT01457547Phase 4
• Immunogenicity and Reactogenicity of DTPa-HBV-IPV/Hib, Compared to DTPa-HBV-IPV and Hib Administered SeparatelyCompletedNCT01457508Phase 3
• Immunogenicity and Safety of DTPa-HBV-IPV/Hib Compared to DTPa-IPV/Hib and HBV Administered ConcomitantlyCompletedNCT01457495Phase 2
• Immunogenicity and Reactogenicity of GSK Bio DTPa-HBV-IPV and Hib Vaccines When Coadministered to Healthy InfantsCompletedNCT00879827Phase 3
• A Post-marketing Safety Study of GSK Bio IPV Vaccine (PoliorixTM) in Korean ChildrenCompletedNCT00514033
• Immunogenicity and Safety of a DTPa-HBV-IPV/Hib Vaccine Given at 2, 3 and 4 Months of AgeCompletedNCT00376779Phase 2
• Immunogenicity & Safety Study of Combined/Separate Vaccine(s) Against Common Diseases in Infants (2,4,6 Months of Age).CompletedNCT00352963Phase 3
• Compare Immunogenicity & Safety of 2 Formulations of GSK Biologicals' DTPa-HBV-IPV/Hib Vaccine Given in Healthy InfantsCompletedNCT00320463Phase 3
• Immunogenicity & Safety of GSK's Combined DTPa-HBV-IPV/Hib Vaccine in Indian Infants at 2 Diff Vaccination SchedulesCompletedNCT00316147Phase 3
• Multicentre Booster & Immune Memory Study of a Booster Dose of GSK Biologicals' 10-valent Pneumococcal Conjugate Vaccine or a Single Dose of 23-valent Plain Polysaccharide Vaccine in Healthy Children Aged 11-18 Mths, Previously Vaccinated in Study 103488CompletedNCT00307567Phase 2
• Post-marketing Safety Study of GSK Biological's Pediarix™ VaccineCompletedNCT00146835